Journal Image
Current Drug Targets
ISSN (Print): 1389-4501
ISSN (Online): 1873-5592
DOI: 10.2174/13894501113146660226      Price:  $58

Pathophysiology and Pharmacologic Treatment of Venous Thromboembolism

Author(s): Jonathan Bain, Douglas R. Oyler, Susan S. Smyth and Tracy E. Macaulay
Pages 199-209 (11)
Venous thrombosis is a common medical disorder affecting nearly one million Americans each year. This review will focus primarily on the formation of venous thrombosis as well as current and future treatment options. While the full pathophysiology of venous thrombosis is not known, recent evidence points to a role for von Willebrand Factor, platelets, and neutrophils in thrombus formation. Many laboratory and imaging tests may be used for the diagnosis of venous thrombosis (VTE), but risk factor identification and clinical examination should not be overlooked as they are vital in assuring accurate treatment and patient identification. Historically heparin followed by a vitamin K antagonist has been the standard of care for treatment of VTE, but increasing data involving factor Xa inhibitors and direct thrombin inhibitors may mean a shift in first-line therapy in the very near future. Invasive therapies such as catheter-directed thrombolysis have also shown promise in the treatment of venous thrombosis and will likely see increased use in the future.
Venous thrombolism, pulmonary embolism, heparin, warfarin, EKOS, factor Xa inhibitors, direct thrombin inhibitors.
Division of Cardiovascular Medicine, The Gill Heart Institute, UK HealthCare, 900 South Limestone, Lexington, Kentucky 40536, USA.